Novel High-Dose Chemotherapy Regimens in Relapsed/Refractory Germ Cell Cancer: Have We Made Progress?
Sequential carboplatin/etoposide-based high-dose chemotherapy with stem cell support is a standard therapy option for relapsed germ cell tumors, resulting in cure for approximately 50% of patients. In a recent single-center phase II study, results were reported for a novel combination including gemcitabine, melphalan, docetaxel, and carboplatin. See related article by Nieto et al., p. 300.
Authors
- Craig R. Nichols (ORCID: https://orcid.org/0000-0002-6256-1511)
- Lucia Nappi (ORCID: https://orcid.org/0000-0002-4365-7251)
- Christian Kollmannsberger (ORCID: https://orcid.org/0000-0002-6329-761X)
Institutions
- BC Cancer Agency (CA)
- University of British Columbia (CA)
- The Prostate Centre (GB)
- Testicular Cancer Commons (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3334
- Primary Topic
- Testicular diseases and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00